Douglas Flora: Lung cancer screening is a perfect early use case for AI tools
“AI can save more lives—Lung cancer screening is a perfect early use case for these tools.
I appreciate you sharing this, Michael Gieske. Important topic, and great expert panel. Hope you guys can join us.
The lung cancer screening team St. Elizabeth Healthcare and St. Elizabeth Physicians continues to lead the way. Over 400 Stage I lung cancers saved so far!
Thank you to the AstraZeneca team, especially Sarah M. Dunlap, Ph.D. for supporting AI in Precision Oncology and this important discussion. Sunil Verma, we want you on our next panel!
Click here to learn more.”
Quoting Michael Gieske‘s
“Join me in attending a gathering of some of the leading innovators and experts in the AI Health space, including our own St. Elizabeth Healthcare Douglas Flora, MD, LSSBB, FACCC, as well as Mass General Cancer Center Dr. Lecia Sequist, co-developer of Sybil, an amazing AI technology that can predict lung cancer up to 6 years out, Dr. Robert Smith – American Cancer Society, Dr. Sarah M. Dunlap, Ph.D., and Dr. Sanjay Juneja, M.D. “
Douglas Flora is the Executive Medical Director of Oncology Services at St. Elizabeth Healthcare, overseeing clinical operations, strategic planning, and the expansion of cancer programs. He is also the co-founder of the Center for Precision Medicine; Genomic Health.As the Editor-in-Chief of ‘AI in Precision Oncology,’ the first peer-reviewed academic journal dedicated to this field, he plays a pivotal role in advancing research. He is also an active board member of the American Cancer Society and ACCC, where he contributes to advocacy, education, and innovation within the cancer community.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023